CLINICAL TRIALS
10+ recruiting Cervical Cancer trials in Massachusetts, simplified into plain English.
Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, c…
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors includ…
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain prelimina…
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTE…
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). Th…
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selec…
Dostarlimab and Cobolimab in Advanced Cervical Cancer
This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.…
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.…
A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer
This research is studying the level of oxygen in tumors during the brachytherapy procedure.…
Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice, RCT
The goal of this PREDICT is to assess a personalize approach to screening and management of cervical cancer testing. The investigators will evaluate patients who are due for a follow up cervical cancer screening in the p…
RECOMMENDED RESOURCES FOR CERVICAL CANCER
Color Health
CLIA Certified
Hereditary cancer genetic testing from $99. Understand your inherited risk for breast, ovarian, colon, and other cancers — with genetic counseling included.
Get Tested →Clinicals AI may earn a referral fee. At no cost to you.
COMMON QUESTIONS
Are there Cervical Cancer clinical trials in Massachusetts?
Yes. Clinicals AI lists 10+ recruiting Cervical Cancer trials in Massachusetts sourced from ClinicalTrials.gov. Browse them above or search across all states.
How do I qualify for a Cervical Cancer trial in Massachusetts?
Eligibility varies by study. Most trials require a confirmed Cervical Cancer diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.
Are Cervical Cancer clinical trials free to join?
Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.